Proactive Investors - Run By Investors For Investors

Redx Pharma in possession of two very valuable assets, Cantor Fitzgerald believes

Redx intends to commercialise its assets through partnerships, out-licensing or co-development at the pre-clinical stage or in early clinical phases
Rogue cells
Redx's first clinical trial application was filed for its Porcupine inhibitor, RXC004, in April

Redx Pharma PLC (LON:REDX) said it expects to continue the good progress made across its research programmes this year.

The company, which restructured in March, saving £4.2mln a year, and focused its efforts on its key assets in oncology and immunology, said it has the funds to continue work on its promising pipeline following the share placing and subscription a couple of months back.

The cash position stood at £5.1mln at the end of March, up from £4.4mlm a year earlier.

WATCH: Redx Pharma 'in a very good place with great assets', says CEO

Iain Ross has only been in the chair since the beginning of May but the non-executive chairman said he had been “impressed by the potential of Redx Pharma's science, approach to drug discovery and the speed with which the company has created a world class pipeline of best-in-class products”.

Ross said that following the recent re-structuring, Redx was now focused on implementing “an aggressive strategy” to accelerate the realisation of value by progressing the clinical and commercial development of our lead programmes and maximising the long term potential of the pipeline.

Dr Neil Murray, chief executive officer of Redx Pharma, added: "Redx Pharma is now optimally positioned to capitalise on the potential of its world class discovery engine with the transition to clinical development of our two best-in-class assets RXC004 and RXC005 in oncology.

“I am also excited by the potential of our pipeline in fibrosis, bringing novel medicines to areas of severe unmet need. We look forward to announcing the start of our first clinical trial with RXC004 and to building greater value for our shareholders as a clinical stage business."

As for the half-year profit & loss numbers, the company is still in the pre-revenue stage and is thus loss-making.

The loss before tax widened in the six months to to 31 March to £10.99mln from £6.64mln the year before.

“2017 is a key year for Redx with a refocusing of resources to ensure that the requisite effort is directed behind key programmes RXC004 (targeting PORC) and RXC005 (a second generation BTK inhibitor,” suggested broker Cantor Fitzgerald.

“These programmes epitomise the breadth and depth of the expertise at Redx with the BTK programme seeking to capitalise on the already well-established haematological cancer market while the PORC programme seeks to deliver a novel approach targeting difficult to treat cancers and potentially also taking Redx into the highly topical fibrosis field,” it added.

“PORC is scheduled to move into the clinic shortly which is clearly a significant achievement for the company. With the BTK programme set to follow later in 2017, Redx will be in full possession of what we believe to two very valuable (multi $bn potential) clinical stage assets,” the broker declared, as it reiterated its ‘buy’ recommendation and 105p target price.

Shares in Redx were up 1.9% at 33.5p in mid-morning trade.

---adds broker comment and share price---

Why Invest In Redx Pharma Plc? Read More Here

Register here to be notified of future REDX Company articles
View full REDX profile View Profile

Redx Pharma Plc Timeline

CN Research
April 06 2017

Related Articles

a child with asthma using an inhaler
September 22 2016
Phase II results for its prospective asthma treatment are due next year, while its LOXL2 collaboration with Pharmaxis is set for a Phase I trial in 2017
picture of pregnant women
May 09 2017
Diclectin is entering a potential £250mln UK/European market with a differentiated product addressing an unmet need.
July 26 2016
Chief executive Cameron Reynolds told Proactive: "It's one thing to be a science project. It's another to have products and we are right on the cusp of that.”

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use